Volume 25, Number 6—June 2019
Research
Assessment of Economic Burden of Concurrent Measles and Rubella Outbreaks, Romania, 2011–2012
Joseph Njau1, Denisa Janta, Aurora Stanescu, Sarah S. Pallas, Adriana Pistol, Nino Khetsuriani2, Susan Reef, Daniel Ciurea, Cassandra Butu, Aaron S. Wallace, and Laura Zimmerman
Table 4
Estimated total costs by component for base case and sensitivity analyses for assessment of economic burden of concurrent measles and rubella outbreaks, Romania, 2011–2012*
| Cost component | Disease or outcome | Main analysis base case | Sensitivity analysis variable | Sensitivity analysis LB | Sensitivity analysis UB | Total measles and rubella costs with LB | Total measles and rubella costs with UB |
|---|---|---|---|---|---|---|---|
| Healthcare provider | Measles | $3,275,757 | Healthcare provider costs | $2,948,181 | $3,603,332 | $9,555,968 | $10,211,120 |
| Rubella | $674,633 | Healthcare provider costs | $607,169 | $742,096 | $9,816,081 | $9,951,007 | |
| National outbreak response | Measles | $516,351 | National outbreak response costs | $464,716 | $567,986 | $9,831,909 | $9,935,179 |
| Rubella | $1,043,623 | National outbreak response costs | $939,261 | $1,147,985 | $9,779,182 | $9,987,906 | |
| Direct medical and nonmedical household | Measles | $883,338 | Out-of-pocket inpatient and outpatient treatment costs | $266,573 | $1,572,347 | $9,266,779 | $10,572,553 |
| Proportion of patients receiving inpatient or outpatient treatment | $716,509 | $915,498 | $9,716,715 | $9,915,704 | |||
| No. cases | $795,004 | $971,672 | $9,795,210 | $9,971,878 | |||
| Rubella | $477,261 | Out-of-pocket inpatient and outpatient treatment costs | $141,497 | $1,136,431 | $9,547,779 | $10,542,713 | |
| Proportion of patients receiving inpatient or outpatient treatment | $310,302 | $768,764 | $9,716,584 | $10,175,046 | |||
| No. cases | $429,535 | $524,988 | $9,835,818 | $9,931,270 | |||
| Indirect household | Measles | $779,917 | No. work days missed by case-patients | $583,614 | $1,068,856 | $9,687,241 | $10,172,484 |
| No. work days missed by caregivers | $622,875 | $897,698 | $9,726,502 | $10,001,325 | |||
| Rubella | $1,043,281 | No. work days missed by case-patients | $827,714 | $1,403,658 | $9,667,976 | $10,243,920 | |
| No. work days missed by caregivers | $959,358 | $1,183,153 | $9,799,621 | $10,023,416 | |||
| CRS cases direct medical | Rubella | $130,143 | Reimbursement to healthcare providers for CRS cases | $47,038 | $194,145 | $9,800,438 | $9,947,546 |
| CRS cases lifetime discounted indirect | Rubella | $1,059,241 | Productive years (labor force participation, unemployment rate) | NA | $2,165,257 | NA | $10,989,560 |
| Total | Measles | $5,455,363 | NA | NA | NA | NA | NA |
| Rubella | $4,428,182 | NA | NA | NA | NA | NA | |
| Both | $9,883,545 | NA | NA | NA | NA | NA |
*CRS, congenital rubella syndrome; LB, lower bound; NA, not applicable; UB, upper bound.
1Current affiliation: JoDon Consulting Group LLC, Atlanta, Georgia, USA.
2Current affiliation: Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Page created: May 20, 2019
Page updated: May 20, 2019
Page reviewed: May 20, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.